NEW YORK (GenomeWeb News) – Exosome Diagnostics has raised $7 million toward a goal of $8.5 million, it said in a regulatory filing on Thursday.
In an amended Form D filed with the US Securities and Exchange Commission, the New York-based molecular diagnostic firm said that the types of securities offered were in the form of debt; option, warrant, or other right to acquire another security; and security toe be acquired upon exercise of option, warrant, or other right to acquire security.
It did not identify the investors in the financing or how the proceeds would be used. Company officials did not respond to a request for comment.
In June, the company said in an SEC document that it raised $6.5 million toward a targeted $8 million raise, and in February, it said in another regulatory filing that it raised $5 million toward a $6 million round. It is unclear if the raise disclosed this week is related to the prior two financing rounds.
Exosome raised $20 million in 2010.